The Centers for Disease Control and Prevention (CDC) in the United States recommended on Wednesday the third booster dose of the Pfizer / BioNTech vaccine against COVID-19 for children between 12 and 15 years old.
This population group will be able to undergo the third injection after they have been completed five months from the second dosethe office stated in its updated recommendations.
This Monday, the Federal Food and Drug Administration (FDA) expanded the authorization for emergency use for minors between 12 and 15 years old.
Earlier yesterday, the CDC’s Advisory Committee on Immunization Practices voted 13 to 1 to uphold the FDA’s recommendation regarding vaccinations for these youth.
Last December, the CDC did the same but for teens ages 16 and 17.
The CDC had authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in ages 16 and 17 in December.
“It is critical that we protect our children and adolescents from COVID-19 infection and the complications of severe illness,” CDC Director Rochelle Walensky said in a news release. “Today, I endorse the vote of the ACIP to expand eligibility and strengthen our recommendations for booster doses. Now, we recommend that all adolescents between the ages of 12 and 17 receive the booster five months after the primary series of vaccines.
Walensky stressed the importance of third dose in the battle against the Omicron variant.
“This booster dose will provide optimal protection against COVID-19 and the Omicron variant. I exhorted all parents to keep their children up to date with the recommendations of the CDC on vaccination against COVID-19, “said the person in charge.
ACIP’s recommendation came after its members examined data on cases of myocarditis and pericarditis in young people who got the COVID-19 vaccine.
The CDC concluded that the risks for this group are greater if they do not get vaccinated.
“The CDC continues to recommend that all people 5 years of age and older get vaccinated against COVID-19. The known risks of COVID-19 and the possible serious complications related to the disease, such as long-term health problems, hospitalizations and even death, outweigh the potential risks of having any rare adverse reactions after vaccination, such as possible risk of myocarditis or pericarditis, ”reads an entry on the CDC website.
The entity established that of the patients with myocarditis or pericarditis who received care responded well to drug treatment and rest and improved rapidly.
It may interest you:
COVID: How long to wait to get the coronavirus vaccine booster if I am infected